The Melanoma Nursing Initiative – Home › Forums › Immunotherapy › Dosing and administration › Infusion times › Reply To: Infusion times
February 12, 2018 at 6:00 pm #4678
Expert NurseRajni Kannan
Currently Nivolumab is approved for 30 min infusion for all melanoma metastic indications as single agent or in combination with Ipilimumab. However, the adjuvant Nivolumab was approved after the 30 min Nivolumab had been submitted to the FDA. Therefore for adjuvant Nivolumab the label states that it should be given over 60 min. There should be an update to the label soon, and adjuvant Nivolumab will be approved for 30 min infusion. There are several studies to support it’s safety in infusing it over 30 min.